7 research outputs found
A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation
Purpose : To evaluate Tocoferol monoglucoside (TMG), a water soluble
vit. E. in a phase I trial, as a radiation protector in those
undergoing hemi-body radiation for disseminated disease. Materials and
Methods: Patients scheduled to receive modified hemi-body radiation
were accrued for the study. Patients not only had disseminated skeletal
disease but, were heavily pretreated Seven patients were accrued for
the study. Patients received 1 and 2 gms of TMG. 30-40 minutes before
hemibody radiation. A dose of 600 cGy was delivered on telecobalt
equipment at mid plane. Immediate Toxicities were evaluated as well as
response to pain. Results: All the seven patients underwent radiation
uneventfully. There was no drug related toxicity. Pain relief was
adequate. Conclusion: Tocoferol monoglucoside an effective antioxidant
with no significant acute toxicity, when administered in a dose of 1 or
2 gms per oral route. TMG being water-soluble can have global
antioxidant and radio protective effects. This needs further clinical
evaluation